• In recent months, Blue Owl Capital Inc. reported first-quarter 2026 results that missed analyst expectations, cut its upcoming dividend, executed share repurchases totaling US$78.58 million since early 2025, and increased its latest quarterly dividend to US$0.23 per share, alongside appointing Deva Mishra to lead its insurance solutions business starting July 6, 2026.
• At the same time, the firm has capped withdrawals in certain private credit funds amid heavy redemption requests, bringing liquidity and credit risks in AI-related and legacy software lending sharply into focus for investors.
• We’ll now examine how the earnings miss, dividend reset, and capped fund redemptions may reshape Blue Owl Capital’s existing investment narrative.

Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

Blue Owl Capital Investment Narrative Recap

To stay invested in Blue Owl Capital today, you have to believe in the long term appeal of private credit, digital infrastructure and permanent capital vehicles, even as near term sentiment is strained. The key short term catalyst now sits in how the firm handles elevated redemption pressure in its private credit funds, while the biggest risk is that liquidity and credit concerns around AI related and legacy software lending further dent confidence. The latest results and dividend reset do not remove that risk.

Among the recent updates, the decision to cap withdrawals at 5% in two large private credit funds is most relevant. It directly intersects with the core catalyst of growing permanent and semi liquid capital, because it tests how resilient that model really is when investors rush for the exit. How Blue Owl balances fund liquidity, portfolio quality and fee revenues from these vehicles will be central to how the story evolves from here.

Yet beneath the headline yield and growth narrative, investors should be aware that private credit fund gates and AI linked exposures...

Blue Owl Capital's narrative projects $3.8 billion revenue and $1.0 billion earnings by 2029. This requires 9.6% yearly revenue growth and an earnings increase of about $0.9 billion from $78.8 million today.

Uncover how Blue Owl Capital's forecasts yield a $14.93 fair value, a 48% upside to its current price.

Exploring Other Perspectives

The most cautious analysts were already assuming slower 7.1% annual revenue growth and a big jump in margins, which looks tougher to accept once you factor in fresh redemption pressures and fee risk.

Explore 9 other fair value estimates on Blue Owl Capital - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Blue Owl Capital research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Blue Owl Capital research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Blue Owl Capital's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.